MedPath

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

Phase 3
Completed
Conditions
Metastatic Cancer
Registration Number
NCT00002708
Lead Sponsor
Radiation Therapy Oncology Group
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving radiation therapy during surgery is more effective than standard radiation therapy in treating brain metastases.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without radiosurgery in treating patients with brain metastases that cannot be removed during surgery.

Detailed Description

OBJECTIVES: I. Compare the overall survival of patients with one unresected brain metastasis treated with conventional whole brain radiotherapy (WBRT) with vs. without a stereotactic radiosurgery (SRS) boost. II. Compare sites of recurrence and cause of death in these patients treated with WBRT followed by SRS vs. WBRT alone.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center and extracranial disease (yes or no). Patients are randomized to one of two treatment arms. Arm I: Patients receive fractionated external beam whole brain irradiation (WBRT) 5 days each week for 3 weeks. Both portals are treated during each radiotherapy session. Patients who still have a solitary lesion with a diameter no greater than 4.0 cm also receive stereotactic radiosurgery within 7 days of completing WBRT. Arm II: Patients receive WBRT only. Patients are followed every 3 months for 1 year, then every 4 months for 2 years, and then annually.

PROJECTED ACCRUAL: A total of 262 patients will be accrued over 2.5-3.75 years for this study. The study may close early if interim analysis after 33% and 67% of patients have been followed for 6 months produces significant results. After 6/14/99 an additional 46 patients with a solitary brain metastasis only will be accrued.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
333
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (258)

University of Alabama Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Comprehensive Cancer Institute of Huntsville

πŸ‡ΊπŸ‡Έ

Huntsville, Alabama, United States

Huntsville Hospital System

πŸ‡ΊπŸ‡Έ

Huntsville, Alabama, United States

Mobile Infirmary Medical Center

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

Urology Associates - Mobile AL

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

MBCCOP - Gulf Coast

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

Alabama Oncology, LLC

πŸ‡ΊπŸ‡Έ

Montgomery, Alabama, United States

Radiation Oncology Associates of West Alabama

πŸ‡ΊπŸ‡Έ

Tuscallosa, Alabama, United States

Providence Cancer Therapy Center

πŸ‡ΊπŸ‡Έ

Anchorage, Alaska, United States

Arizona Cancer Center

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Scroll for more (248 remaining)
University of Alabama Comprehensive Cancer Center
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.